NCT06266091View on ClinicalTrials.gov

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

PHASE2CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

November 24, 2021

Primary Completion Date

February 14, 2024

Study Completion Date

August 1, 2024

Conditions
Malignant Ascites
Interventions
DRUG

M701

Intra-peritoneal infusion of M701 combined with system therapy

DRUG

paracentesis

paracentesis combined with system therapy

Trial Locations (1)

100141

The First Medical Center of Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Wuhan YZY Biopharma Co., Ltd.

INDUSTRY

NCT06266091 - Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody | Biotech Hunter | Biotech Hunter